Aug 262020
 

From 23 to 29 August the Ministry of Defence of the Russian Federation is holding the International Military and Technical Forum «Army-2020» in Moscow. This event has gathered not only experts in military field but also all people interested in high-tech developments of Russian defence industry. Director General of Almazov Centre, Academician of the Russian Academy of Sciences Evgeny Shlyakhto attended the Forum.

After the opening ceremony and the Army Games, an official part took place, attended by top public officials, heads of state authority, industrial enterprises and foreign delegations.

As part of the Forum, Prof. Shlyakhto presented the joint development of Almazov Centre and the Russian Federal Nuclear Centre – All-Russia Research Institute of Experimental Physics (a ROSATOM’s company), the Tianox nitric oxide device.

The history of clinical use of nitric oxide goes back more than 30 years, and over this time it has shown not only high effectiveness in intensive therapy of pulmonary arterial hypertension but also a wide range of new effects and application areas. The method for bedside generation of nitric oxide from atmospheric air, recently developed by the All-Russia Research Institute of Experimental Physics, completely eliminates the logistic stage of delivering the nitric oxide, storing it and collecting the empty cylinders. Besides, this production technology contributes to patient safety. Since 2019, Almazov Centre has been successfully using the device as part of its clinical trials.

“The Tianox nitric oxide inhalation device is a life-saving technology that can be used to treat various diseases, including the new coronavirus infection. One of the critical tasks in the treatment of COVID-19 patients is to prevent severe complications, therefore this technique should be used as early as possible. We very much hope that in the near future hospitals treating coronavirus patients with severe forms of the disease will benefit from this opportunity. This will save many lives. In addition, the introduction of this technology into practice will help provide nitric oxide inhalation technology to specialized cardiology clinics, critical care centres, regional and city cardiac surgery centres, level 3 perinatal centres as well as neonatal intensive care units in level 2 obstetric hospitals,” thinks Evgeny Shlyakhto.